<DOC>
	<DOCNO>NCT00336934</DOCNO>
	<brief_summary>RATIONALE : Pomegranate extract may keep prostate cancer grow patient rise prostate-specific antigen ( PSA ) level surgery radiation therapy localize prostate cancer . PURPOSE : This randomized trial study well pomegranate extract work treat patient rise PSA level surgery radiation therapy localize prostate cancer .</brief_summary>
	<brief_title>Pomegranate Extract Treating Patients With Rising Prostate-Specific Antigen Levels After Surgery Radiation Therapy Localized Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Evaluate effect pomegranate extract patient rise prostate-specific antigen ( PSA ) level surgery radiotherapy localize prostate cancer . - Determine effect daily oral dose pomegranate extract absolute value PSA change PSA doubling time patient . Secondary - Assess toxicity associate daily oral dose pomegranate extract patient . - Determine effect pomegranate extract positive PSA doubling-time outcome , define great 150 % baseline negative post-treatment PSA doubling time ( i.e. , decline PSA ) . OUTLINE : This multicenter , double-blind , placebo-controlled , randomize study . Patients stratify accord participate center . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral pomegranate extract daily . - Arm II : Patients receive oral placebo daily . Treatment arm continue 1 year absence disease progression . PROJECTED ACCRUAL : A total 180 patient accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma prostate Must complete prior surgery , cryotherapy , radiotherapy primary tumor Documented rise prostatespecific antigen ( PSA ) Absolute level PSA &gt; 0.2 ng/mL surgery Absolute level PSA &gt; 1.0 ng/mL radiation cryotherapy Absolute level PSA ≥ 0.4 ng/mL multiple treatment modality ( e.g. , surgery radiotherapy radiotherapy cryotherapy ) PSA must ≥ 100 % best nadir achieve PSA double time &gt; 3 month ≤ 24 month Patients must ≥ 3 rise PSA time point minimum nadir achieve ≥ 6 month The interval PSA time point must &gt; 2 week PSA ≤ 7.0 ng/mL Patients underwent radical prostatectomy never achieve undetectable serum PSA surgery eligible Gleason score ≤ 7 No histologically positive lymph nod No evidence metastatic disease physical examination , CT scan , bone scan PATIENT CHARACTERISTICS : Life expectancy ≥ 6 month ECOG performance status 0 1 No significant concomitant medical psychiatric condition would limit study compliance No known allergy pomegranate extract No known diabetes hemoglobin A_1c level &gt; 7.0 % past 3 month Diabetic patient enter study hemoglobin A_1c level measure past 3 month must level measure study initiation No clinically abnormal laboratory value &gt; 2 time upper limit normal PRIOR CONCURRENT THERAPY : See Disease Characteristics More 4 week since prior concurrent experimental drug , highdose steroid , cancer treatment No hormonal therapy , exception neoadjuvant androgendeprivation therapy ( ADT ) , prior concurrent primary therapy Patients receive prior neoadjuvant ADT must serum testosterone ≥ 150 ng/dL No prior concurrent hormonal therapy rise PSA primary therapy prostate cancer No finasteride dutasteride time point primary therapy study therapy No concurrent commercial pomegranate product No concurrent systemic local therapy prostate cancer Concurrent dietary/herbal supplement ( e.g. , saw palmetto selenium ) allow provide dose stable ≥ 2 month prior study entry plan change stop supplement study therapy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage II prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
</DOC>